The Robot Investor

The Robot Investor

The Robot Investor breaks down the fast-moving world of robotics and humanoid-robot investing for everyday investors — no finance degree required. Each week, analyst Elena and curious investor Theo unpack the headlines in a Friday news roundup and take a closer look at one company in twice-weekly deep dives, weighing the bull case against the bear case in plain English. From Tesla's Optimus and Nvidia to the supply-chain names quietly powering the boom, we cut through the hype to ask what would actually have to go right — and what could go wrong. Honest, balanced, and a little bit fun. Both ho

  1. 1d ago

    Novanta (NOVT): Selling Muscles To Humanoid Makers | Aug 18, 2026

    Novanta Inc. (NASDAQ: NOVT) sits at Layer 3 of the robotics stack — actuation and precision motion. It doesn't sell robots; it sells the encoders, precision motors, servo drives, force-torque sensors and robotic tool changers that go inside other companies' machines. Founded in Massachusetts in 1968 as General Scanning and renamed Novanta in 2016, it's the kind of company you've never heard of that ships inside the ones you have. On its August 6 earnings call, Novanta disclosed its first significant servo-drive orders supporting the deployment of hundreds of humanoid robots in customer testing facilities — then immediately said those orders were "not a significant part of what drove the margin this quarter." Elena and Theo unpack that tension. The bull case: the strongest organic growth since early 2023 at 9.3%, robotics and automation revenue up 13.5%, automation gross margin up 450 basis points, a $1.13 billion backlog, and a genuine Nvidia safety-lab relationship. The bear case: Novanta just spent up to $1.45 billion buying a surgical suture business, taking medical from 51% to about 60% of revenue — shrinking robotics from roughly a third of the company. Leverage went from net cash to 2.7x in a single quarter, adjusted net income grew 33% while adjusted earnings per share grew only 17% because of dilution, and the stock has returned under 2% a year over five years. What to watch: the robotics growth rate, medical book-to-bill above 1.0, any quantified humanoid disclosure, the gap between reported and adjusted earnings, and the share count. Hosted by AI. Researched and written by AI from credible public sources — we can get things wrong, so verify with primary sources. Not investment advice.

  2. 6d ago

    Amazon (AMZN): A Million Robots, Zero Robot Revenue — Layer 10 Deep Dive | 13 Aug 26

    Amazon has deployed more than a million robots across its network since 2012 — the largest commercial robotics fleet on earth — and earns exactly nothing from selling them. In this deep dive, Elena and Theo place Amazon at Layer 10 of the robotics stack, the full-stack operator layer, and work through what that actually means for a casual investor. The bull case: a business compounding at scale (Q2 2026 net sales of $200.6B, up 20%; operating income $27.5B, up 43%; AWS up 37% to $42.2B with a $496B backlog), plus automation as a margin lever. CFO Brian Olsavsky told investors on the July 30 call that Amazon will more than double its robotic-arm fleet in 2026. Morgan Stanley's Brian Nowak has estimated $2–4B+ of annual recurring fulfilment efficiencies by 2027, rising to $4.5–9B a year by 2030 under his base case. The bear case gets equal weight: reported internal plans to automate 75% of operations and avoid hundreds of thousands of future hires carry real political and regulatory risk; Amazon cut roles in its own robotics division in March 2026 and the Blue Jay arm system has been reported as discontinued; and the entire programme sits inside a ~$220B capital spending year that pushed trailing free cash flow to an outflow of roughly $7.6B. We also unpack why Amazon's trailing P/E of about 22 looks deceptively cheap once you account for the $53.4B non-operating Anthropic gain. Verdict on the "robotics core vs. option" question, plus a four-item watch list: next-gen building count against the ~40-facility 2027 plan, arm-fleet execution, North America retail operating margin as the automation fingerprint, and 2027 capex guidance. Hosted by AI. Researched and written by AI from credible public sources — we can get things wrong, so verify with primary sources. Not investment advice.

  3. Aug 4

    Mobileye (MBLY): The $900M Humanoid Bet | Aug 04, 2026

    Mobileye Global (NASDAQ: MBLY) sits at Layer 6 of the robotics value chain — mobile and autonomous-vehicle robotics. Its EyeQ chips sit behind the windshield of tens of millions of cars, powering automatic emergency braking, lane keeping and hands-free highway driving, and it shipped roughly 10 million units last quarter alone. In January 2026 it spent about $900 million buying Mentee Robotics, an Israeli humanoid-robot startup co-founded by Mobileye's own CEO. In July it announced it will build and operate its own robotaxi fleet. Elena and Theo unpack a second quarter that beat on both revenue and earnings, raised full-year guidance — and still saw the stock fall 16.5% in a single session — its steepest drop since August 2024 — after founder Amnon Shashua announced he is stepping down as CEO after 27 years and the company guided third-quarter revenue down roughly 5-6% year over year. The bull case: real automotive-scale volume, $1.4 billion in cash, margin-rich upmarket design wins including Stellantis, a durable Israeli R&D incentive, and two option values the market is currently pricing near zero. The bear case: flat revenue, falling EyeQ average selling prices, gross margin down from 50% to 46%, Chinese competitors taking share on cost, a $3.79 billion non-cash goodwill impairment tied to Intel's 2017 acquisition, Intel still holding roughly 77% of the shares and 97% of the voting power, and post-earnings analyst targets ranging from $7 to $18. We also give the honest verdict casual investors need: this is a robotics option, not a robotics thesis — humanoid and robotaxi revenue today is zero. Hosted by AI. Researched and written by AI from credible public sources — we can get things wrong, so verify with primary sources. Not investment advice.

About

The Robot Investor breaks down the fast-moving world of robotics and humanoid-robot investing for everyday investors — no finance degree required. Each week, analyst Elena and curious investor Theo unpack the headlines in a Friday news roundup and take a closer look at one company in twice-weekly deep dives, weighing the bull case against the bear case in plain English. From Tesla's Optimus and Nvidia to the supply-chain names quietly powering the boom, we cut through the hype to ask what would actually have to go right — and what could go wrong. Honest, balanced, and a little bit fun. Both ho

You Might Also Like